[Carcinoma of the urinary bladder. Konservative oder operative Therapie bei PT1G3].
As no prospective randomised studies are available on therapy and outcome in T1G3 carcinoma of the urinary bladder, a decision on therapy can only be made on the basis of retrospective studies or with reference to the individual experience of a particular urologist. In this paper the advantages and disadvantages of primary cystectomy and of transurethral resection, both alone and in combination with BCG instillation, are discussed and compared.
Miller
K
K
Urologische Klinik, Charité, Campus Benjamin Franklin, Berlin. kurt.miller@charite.de
Hautmann
R
R
D001500:BCG Vaccine / Q000008:administration & dosage*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D015653:Cystectomy; D003558:Cystoscopy; D018450:Disease Progression; D006801:Humans; D020360:Neoadjuvant Therapy; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000473:pathology / Q000601:surgery; D009367:Neoplasm Staging; D012189:Retrospective Studies; D001749:Urinary Bladder Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*
D001500:BCG Vaccine